Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:1324 |
Name | lung cancer |
Definition | A respiratory system cancer that is located_in the lung. |
Source | DiseaseOntology.org |
Alt Ids | DOID:13075 DOID:9881 DOID:1322 |
Path | disease disease of cellular proliferation cancer organ system cancer respiratory system cancer lung cancer |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01014598 | Phase I | Cisplatin | Cisplatin in Treating Patients With Lung Cancer | Completed | USA | 0 |
NCT01218867 | Phase Ib/II | Anti-VEGFR2 CAR CD8 lymphocytes Cyclophosphamide Fludarabine Aldesleukin | Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes | Terminated | USA | 0 |
NCT01366144 | Phase I | Paclitaxel Veliparib Carboplatin | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | Active, not recruiting | USA | 0 |
NCT01386580 | Phase Ib/II | 2B3-101 2B3-101 + Trastuzumab | An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma. | Completed | USA | 3 |
NCT01470209 | Phase I | Buparlisib + Everolimus | A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies | Completed | USA | 0 |
NCT01859026 | Phase I | Binimetinib + Erlotinib | A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation | Active, not recruiting | USA | 0 |
NCT01935336 | Phase II | Ponatinib | Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers | Active, not recruiting | USA | 0 |
NCT01999985 | Phase I | Afatinib + Dasatinib | Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC) | Completed | USA | 0 |
NCT02047747 | Phase II | Dacomitinib | A Phase II Study of Dacomitinib in Progressive Brain Metastases | Terminated | USA | 0 |
NCT02155465 | Phase Ib/II | Erlotinib + Ruxolitinib | Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib | Completed | USA | 0 |
NCT02241369 | Phase I | INO-3106 + INO-9012 | Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies | Completed | USA | 0 |
NCT02264236 | Phase Ib/II | Montanide ISA 51 + P10s-PADRE | Vaccination of Advanced-Stage Lung Cancer Patients | Recruiting | USA | 0 |
NCT02310464 | Phase I | OBI-821 + OBI-833 | Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects | Recruiting | USA | 1 |
NCT02429843 | Phase I | Carboplatin + Paclitaxel Bevacizumab Carotuximab | A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT02433626 | Phase I | COTI-2 Cisplatin + COTI-2 | Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101) | Unknown status | USA | 0 |
NCT02538627 | Phase I | Seribantumab MM-151 | Phase 1 Combination Study of MM-151 and MM-121 | Terminated | USA | 0 |
NCT02576431 | Phase II | Larotrectinib | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE) | Recruiting | USA | CAN | 28 |
NCT02675829 | Phase II | Ado-trastuzumab emtansine | Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers | Recruiting | USA | 0 |
NCT03188965 | Phase I | BAY1895344 | First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas | Recruiting | USA | CAN | 7 |
NCT03199586 | Phase I | NP-G2-044 | Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma) | Completed | USA | 0 |
NCT03373760 | Phase II | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer | Recruiting | USA | 0 |
NCT03477162 | Phase 0 | Metformin | Metformin Pharmacology in Human Cancers: A Proof of Principle Study | Recruiting | USA | 0 |
NCT03597009 | Phase Ib/II | Nivolumab + Talimogene laherparepvec | A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion | Recruiting | USA | 0 |
NCT03719768 | Phase I | Avelumab | Avelumab With Radiotherapy in Patients With Leptomeningeal Disease | Recruiting | USA | 0 |
NCT04085315 | Phase I | Alisertib + Osimertinib | Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer | Recruiting | USA | 0 |
NCT04148937 | Phase I | LY3475070 LY3475070 + Pembrolizumab | A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer | Recruiting | USA | 2 |
NCT04259450 | Phase Ib/II | AFM24 | Study to Assess AFM24 in Advanced Solid Cancers | Recruiting | USA | 2 |
NCT04273061 | Phase II | Atezolizumab | Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity (CAPTIV-8) | Recruiting | CAN | 0 |
NCT04287868 | Phase Ib/II | M7824 + NHS-IL12 + PDS0101 | Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies | Recruiting | USA | 0 |
NCT04396821 | Phase I | TST001 | A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |